HealthRX.com · Printable lab tracker
Wegovy kidney tracker: eGFR, urine albumin and fluid losses
Record your starting eGFR, urine albumin and kidney-affecting medicines, then add each result with the Wegovy dose and any vomiting or diarrhea before the test, so a single low reading can be judged against the trend and against dehydration.
Your kidney baseline
eGFR and creatinine before Wegovy, with date
Urine albumin-to-creatinine ratio (UACR), with date
Blood pressure and diabetes status
Medicines that affect the kidneysNSAIDs, water pills, ACE inhibitors or ARBs, SGLT2 inhibitors
Kidney results over time
A low reading drawn after a day of vomiting or poor drinking is worth repeating once you are rehydrated.
| Date | Wegovy dose | eGFR | Creatinine | UACR | Blood pressure | Vomiting or diarrhea in the 3 days before? |
|---|---|---|---|---|---|---|
What SELECT and the label report
- SELECT, semaglutide 2.4 mg: eGFR declined 0.75 mL/min/1.73 m² less than on placebo by 104 weeks.[1]
- SELECT: urine albumin rose less on semaglutide, a net difference of 10.7% at 104 weeks.[1]
- SELECT: the main kidney composite occurred in 1.8% on semaglutide versus 2.2% on placebo (hazard ratio 0.78).[1]
- SELECT found no excess of acute kidney failure on semaglutide, whatever the starting eGFR.[1]
- The Wegovy label reports acute kidney injury after dehydration from stomach side effects, sometimes needing dialysis, and says to monitor kidney function when that happens.[2]
Call your healthcare provider for
- Vomiting or diarrhea that stops you keeping fluids down, little or dark urine, or dizziness on standing: dehydration can injure the kidneys.[2]
Questions about my kidney numbers
- Is this eGFR change bigger than the normal test-to-test variation for me?
- Should we repeat the test after I am well hydrated before deciding anything?
- Should my urine albumin be checked as well as eGFR, and how often?
- Do any of my medicines need adjusting while I am losing weight or having stomach side effects?
- Given my diabetes status, which trial results apply to me more closely, SELECT or FLOW?
Sources for the facts on this sheet
- Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024. PMID 38796653. https://pubmed.ncbi.nlm.nih.gov/38796653/
- Novo Nordisk, via DailyMed. Wegovy (semaglutide) injection, for subcutaneous use, and Wegovy (semaglutide) tablets, for oral use: prescribing information and Medication Guide. Effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.